Isomorphic Labs
An AI drug design engine (IsoDDE) that goes beyond AlphaFold-style structure prediction to design molecules across therapeutic areas and modalities; Alphabet spinout run by Demis Hassabis.
- Founded
- November 2021
- Headquarters
- London, UK
- Founders
- Demis Hassabis
- Pushes against
- Drug discovery as a screening-heavy wet-lab process.
- Now
- Raised a $2.1B Series B on 2026-05-12, led by Thrive. It is advancing drug design programs across multiple therapeutic areas and has not announced a clinical-stage milestone.
Key people
- Demis Hassabis (founder, CEO)
Funding
- 17 November 2026 announced
- Amount
- $5 billion
- Lead
- Greenoaks and Sequoia Capital co-led, with Andreessen Horowitz, Alphabet, GV, CapitalG, Thrive Capital, MGX, Temasek and others
- 12 May 2026
- Amount
- $2.1B Series B
- Lead
- Thrive Capital (Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund)
- 31 March 2025
- Amount
- $600M, first external round
- Lead
- Thrive Capital (GV; Alphabet follow-on)
Every funding round in the Atlas
Sources
- isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round
- isomorphiclabs.com/articles/isomorphic-labs-announces-600m-external-investment-round
- en.wikipedia.org/wiki/Isomorphic_Labs
This profile was checked and corrected against its sources on 6 October 2026. How we check